Predict your next investment

Corporation
HEALTHCARE | Drug Development
merck.com

See what CB Insights has to offer

Investments

20

Portfolio Exits

21

Partners & Customers

10

About Merck & Co.

Merck & Co. (NYSE: MRK) is a global healthcare company. Through its prescription medicines, vaccines, biologic therapies, and animal health products, the company works with customers and operates in more than 140 countries to deliver health solutions. Merck & Co. was originally a subsidiary of Merck Group before becoming independent in 1917.

Merck & Co. Headquarter Location

2000 Galloping Hill Road

Kenilworth, New Jersey, 07033,

United States

908-740-4000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Merck & Co.

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Merck & Co. in 4 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

Merck & Co. Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Merck & Co. Rank

Research containing Merck & Co.

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Merck & Co. in 4 CB Insights research briefs, most recently on May 5, 2021.

Latest Merck & Co. News

ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda

Sep 20, 2021

September 20, 2021 There’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the tree in previously-untreated non-small cell lung cancer (NSCLC). Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Libtayo (cemiplimab) given in combination with chemotherapy looks broadly to have matched Keytruda (pembrolizumab) plus chemo in newly-diagnosed people with metastatic NSCLC , reducing the risk of death by 29% versus chemo alone in the phase 3 EMPOWER-Lung-3 study. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on its own, while progression-free survival was eight and five months respectively, a 46% improvement. That’s less impressive than the 50% reduction in death in Merck’s KEYNOTE-189 trial of Keytruda in non-squamous NSCLC – which was behind its approval for first-line NSCLC alongside chemo in 2018 – but in the same ballpark as the 36% reduction seen in the KEYNOTE-407 trial in squamous NSCLC. EMPOWER-Lung-3 enrolled subjects with both squamous and non-squamous tumours and all PD-L1 expression levels, so Libtayo’s efficacy comes against a more heterogenous patient population. On the other hand, it also included patients with less advanced disease than the Keytruda trials that – hypothetically at least – could have pushed the overall survival numbers up. Drawing any comparisons between studies is always a challenge, and the bottom line is that Libtayo/chemo joins a select group of PD-1/PD-L1 drugs that have shown efficacy in first-line NSCLC. It is the only other than Keytruda to improve survival in previously-untreated patients irrespective of histology both as monotherapy and in combination with chemo, according to Sanofi and Regeneron. The combination also achieved a 43% response rate compared with 23% for chemo alone, with a duration of response of 16 months versus seven months, respectively. Libtayo – the sixth PD-L/PD-L1 inhibitor to reach the market – is already approved to treat newly-diagnosed advanced NSCLC patients with 50% or more PD-L1 expression along with a couple of other skin cancer indications. The new trial could give it a much better chance of competing with Keytruda in first-line NSCLC – one of the biggest markets in cancer – although Merck’s established presence and the familiarity of oncologists with Keytruda will doubtless be hard to overcome. Other rivals are also trying to grab a slice of the first-line NSCLC market however, including Bristol-Myers Squibb’s combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab), Roche’s Tecentriq (atezolizumab), AstraZeneca’s Imfinzi (durvalumab)/tremelimumab combination, and a regimen based on Innovent’s Tyvyt (sintilimab) and Eli Lilly’s Alimta (pemetrexed). Analysts have previously suggested Libtayo could capture up to $1 billion in sales from the NSCLC category as a monotherapy alone, and the Empower-Lung-3 combo data has just delivered what looks likely to be an upside to those projections. Don't miss your daily pharmaphorum news.

Merck & Co. Investments

20 Investments

Merck & Co. has made 20 investments. Their latest investment was in Seattle Genetics as part of their Corporate Minority - P2P on September 9, 2020.

CBI Logo

Merck & Co. Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/14/2020

Corporate Minority - P2P

Seattle Genetics

$1,000M

Yes

8

7/17/2020

Series B

SAB Biotherapeutics

$14M

Yes

South Dakota Equity Partners, and Undisclosed Investors

5

6/29/2020

Series C

Yumanity Therapeutics

$21.62M

Yes

Alexandria Venture Investments, Dolby Family Ventures, Fidelity Investments, Pfizer Venture Investments, Redmile Group, and Tony Coles

3

3/2/2020

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

4/18/2019

Milestone Payment

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/14/2020

7/17/2020

6/29/2020

3/2/2020

4/18/2019

Round

Corporate Minority - P2P

Series B

Series C

Unattributed

Milestone Payment

Company

Seattle Genetics

SAB Biotherapeutics

Yumanity Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$1,000M

$14M

$21.62M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

South Dakota Equity Partners, and Undisclosed Investors

Alexandria Venture Investments, Dolby Family Ventures, Fidelity Investments, Pfizer Venture Investments, Redmile Group, and Tony Coles

Sources

8

5

3

10

10

Merck & Co. Portfolio Exits

21 Portfolio Exits

Merck & Co. has 21 portfolio exits. Their latest portfolio exit was SAB Biotherapeutics on June 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/22/2021

Acq - Pending

$991

2

3/22/2021

Acquired

$991

10

9/21/2020

Acquired

$991

18

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

6/22/2021

3/22/2021

9/21/2020

00/00/0000

00/00/0000

Exit

Acq - Pending

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

10

18

10

10

Merck & Co. Acquisitions

38 Acquisitions

Merck & Co. acquired 38 companies. Their latest acquisition was Organon & Co on June 03, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/3/2021

Acquired - II

Spinoff / Spinout

2

4/1/2021

IPO

$991

$138M

Acq - P2P

18

11/23/2020

Series B

$991

$74M

Acquired

4

11/5/2020

Series B

Subscribe to see more

$991

$99M

Subscribe to see more

10

7/1/2020

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/3/2021

4/1/2021

11/23/2020

11/5/2020

7/1/2020

Investment Stage

Acquired - II

IPO

Series B

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$138M

$74M

$99M

$99M

Note

Spinoff / Spinout

Acq - P2P

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

18

4

10

10

Merck & Co. Partners & Customers

10 Partners and customers

Merck & Co. has 10 strategic partners and customers. Merck & Co. recently partnered with f-star Biotechnology on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/4/2021

Partner

f-star Biotechnology

Austria

1

7/29/2021

Partner

Bayer

Germany

1

7/12/2021

Partner

OncoSec Medical

United States

1

7/9/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/6/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/4/2021

7/29/2021

7/12/2021

7/9/2021

7/6/2021

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

f-star Biotechnology

Bayer

OncoSec Medical

Country

Austria

Germany

United States

Subscribe to see more

Subscribe to see more

News Snippet

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Merck & Co. Team

79 Team Members

Merck & Co. has 79 team members, including current Chief Executive Officer, Kenneth C Frazier.

Name

Work History

Title

Status

Kenneth C Frazier

Chief Executive Officer

Current

Sanat Chattopadhyay

President, Executive Vice President

Current

Frank Clyburn

President, Executive Vice President

Current

Robert M. Davis

President

Current

Jannie Oosthuizen

President

Current

Name

Kenneth C Frazier

Sanat Chattopadhyay

Frank Clyburn

Robert M. Davis

Jannie Oosthuizen

Work History

Title

Chief Executive Officer

President, Executive Vice President

President, Executive Vice President

President

President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.